➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Harvard Business School
Moodys
Boehringer Ingelheim
AstraZeneca

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

TAZVERIK Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Tazverik, and when can generic versions of Tazverik launch?

Tazverik is a drug marketed by Epizyme Inc and is included in one NDA. There are twenty patents protecting this drug.

This drug has two hundred and sixty-nine patent family members in thirty-eight countries.

The generic ingredient in TAZVERIK is tazemetostat hydrobromide. Additional details are available on the tazemetostat hydrobromide profile page.

US ANDA Litigation and Generic Entry Outlook for Tazverik

Tazverik will be eligible for patent challenges on January 23, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 11, 2033. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Summary for TAZVERIK
International Patents:269
US Patents:20
Applicants:1
NDAs:1
DailyMed Link:TAZVERIK at DailyMed
Drug patent expirations by year for TAZVERIK
Generic Entry Opportunity Date for TAZVERIK
Generic Entry Date for TAZVERIK*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for TAZVERIK

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes   Start Trial   Start Trial   Start Trial
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes   Start Trial   Start Trial   Start Trial
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes   Start Trial   Start Trial   Start Trial
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes   Start Trial   Start Trial   Start Trial
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Dow
McKinsey
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.